Gastroenterology Clinics of North America
Volume 35, Issue 4 , Pages 735-741, December 2006

Biologics for Inflammatory Bowel Disease: Drug Approval and Monitoring in the United States

Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, 200 1st Street, SW, Rochester, MN 55905, USA

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 William Tremaine, MD receives research support from Procter and Gamble, Inc. He is a consultant for NPS Pharmaceuticals. He is a coinvestigator in current studies sponsored by Celltech, Protein Design Labs, Inc., UCB Pharma, Inc., Otsuka America, and Shire Pharmaceuticals.

PII: S0889-8553(06)00086-0

doi:10.1016/j.gtc.2006.09.010

Gastroenterology Clinics of North America
Volume 35, Issue 4 , Pages 735-741, December 2006

Article Tools

* Image Usage & Resolution